EntryPoint Capital LLC Buys Shares of 191,429 Autolus Therapeutics plc (NASDAQ:AUTL)

EntryPoint Capital LLC purchased a new position in shares of Autolus Therapeutics plc (NASDAQ:AUTL) in the 4th quarter, Holdings Channel.com reports. The institutional investor purchased 191,429 shares of the company’s stock, valued at approximately $450,000.

Several other institutional investors and hedge funds also recently made changes to their positions in AUTL. Wellington Management Group LLP lifted its holdings in Autolus Therapeutics by 35.4% during the third quarter. Wellington Management Group LLP now owns 24,220,226 shares of the company’s stock valued at $87,919,000 after purchasing an additional 6,330,392 shares during the last quarter. FMR LLC raised its position in shares of Autolus Therapeutics by 44.6% in the third quarter. FMR LLC now owns 17,773,873 shares of the company’s stock valued at $64,519,000 after purchasing an additional 5,478,706 shares during the period. Candriam S.C.A. purchased a new stake in shares of Autolus Therapeutics during the 4th quarter valued at approximately $7,500,000. JPMorgan Chase & Co. boosted its holdings in Autolus Therapeutics by 145.3% in the 3rd quarter. JPMorgan Chase & Co. now owns 1,284,708 shares of the company’s stock worth $4,663,000 after buying an additional 761,008 shares during the period. Finally, State Street Corp grew its stake in Autolus Therapeutics by 1.7% in the 3rd quarter. State Street Corp now owns 606,544 shares of the company’s stock valued at $2,202,000 after buying an additional 10,401 shares in the last quarter. Institutional investors own 72.83% of the company’s stock.

Autolus Therapeutics Stock Down 5.3 %

Shares of NASDAQ AUTL opened at $1.62 on Wednesday. The stock’s 50-day simple moving average is $2.00 and its two-hundred day simple moving average is $2.87. Autolus Therapeutics plc has a twelve month low of $1.56 and a twelve month high of $6.48. The firm has a market capitalization of $431.07 million, a P/E ratio of -1.34 and a beta of 2.07.

Autolus Therapeutics (NASDAQ:AUTL) last posted its quarterly earnings data on Thursday, March 20th. The company reported ($0.09) earnings per share for the quarter, topping the consensus estimate of ($0.21) by $0.12. The company had revenue of $0.03 million during the quarter, compared to the consensus estimate of $2.98 million. As a group, research analysts anticipate that Autolus Therapeutics plc will post -0.94 EPS for the current fiscal year.

Analyst Upgrades and Downgrades

AUTL has been the topic of a number of analyst reports. Needham & Company LLC restated a “buy” rating and set a $10.00 target price on shares of Autolus Therapeutics in a research report on Monday, January 13th. Wells Fargo & Company dropped their price objective on Autolus Therapeutics from $8.00 to $6.00 and set an “overweight” rating on the stock in a report on Friday, March 21st. Six analysts have rated the stock with a buy rating, According to MarketBeat.com, the stock currently has an average rating of “Buy” and a consensus target price of $9.52.

Autolus Therapeutics Profile

Autolus Therapeutics plc, a clinical-stage biopharmaceutical company, develops T cell therapies for the treatment of cancer and autoimmune diseases. The company's clinical-stage programs include obecabtagene autoleucel (AUTO1), a CD19-targeting programmed T cell investigational therapy that is in Phase 1b/2 clinical trial for the treatment of adult ALL; AUTO1/22, which is in a Phase 1 clinical trial in pediatric patients with relapsed or refractory ALL; AUTO4, a programmed T cell investigational therapy for the treatment of peripheral T-cell lymphoma targeting TRBC1 and TRBC2; AUTO6NG, a programmed T cell investigational therapy targeting GD2 in development for the treatment of neuroblastoma; and AUTO8, a product candidate to treat multiple myeloma.